Workflow
Silexion Therapeutics Corp(SLXN) - 2025 Q2 - Quarterly Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-42253 SILEXION THERAPEUTICS CORP (Exact name of registrant as specified in its charter) Washington, D.C. 20549 | CERTAIN TERMS | Page ii | | --- | --- | | SPE ...